RxDoctor Payments Data

Angelina Gangestad, MD

Obstetrics & Gynecology · Cleveland, OHNPI 1952334476

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,435 of the $1,983 with a category attached, or 72.4%. 20 manufacturers reported payments, led by Bayer at 48.7% of the total. 2025 is the largest year on record at $950, 6.5 times the $147 reported in 2019.

$1,983in general payments, 2019–2025

Across 60 payments — averaging $33.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$966
  • AbbVie$234
  • Astellas Pharma US Inc$99
  • Sumitomo Pharma America, Inc.$89
  • Myovant Sciences Inc.$79
  • Organon$77
  • plus $439 from 14 others
$772,478in research payments, 2019–2025

Across 310 payments — averaging $2491.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$472K
  • Medicines360$94K
  • Sumitomo Pharma America, Inc.$63K
  • Mitsubishi Tanabe Pharma Development America, Inc.$51K
  • Genbiopro, Inc.$48K
  • Abbott$44K

What the payments were for

  • Travel & lodging$54728%
  • Food & beverage$1,43572%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,983 in reported general payments places this provider in the 75th percentile of 1,376 obstetrics & gynecology providers in Ohio.

See all obstetrics & gynecology providers in Ohio

Medicare billing

Part B allowed, 2024
$3,820
Medicare patients
50
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremproEstrogen,con/M-Progest Acet11$4,458
Estradiol21$1,709
Raloxifene Hcl15$624
Trospium Chloride ErTrospium Chloride12$456
Medroxyprogesterone Acetate11$429
Fluconazole18$83

Paid to pharmacies, not to this prescriber.

Other obstetrics & gynecology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →